I N V A C A R E C O R P O R A T I O N
Presentation (NYSE: IVC)
t e m b e r 9 , 2 0 2 0
I N V A C A R E C O R P O R A T I O N
This presentation contains forward-looking statements within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those that describe future outcomes or expectations that are usually identified by words such as "will," "should," "could," "plan," "intend," "expect," "continue," "forecast," "believe," and "anticipate" and include, for example, any statement made regarding the company's future results. Actual results may differ materially as a result of various risks and uncertainties, including those expressed in the cautionary statement in the company's earnings press release for the second quarter 2020 posted on www.invacare.com/investorrelations, as well as in the company's annual reports on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. The company may not be able to predict and may have little or no control over many factors or events that may influence its future results and, except as required by law, shall have no obligation to update any forward-looking statements.
Financial results presented are as of June 30, 2020, unless otherwise noted.
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Making Life's
Experiences Possible
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
ABOUT US
Headquartered in Elyria, OH (outside of Cleveland), Invacare is proudly celebrating its 40th year of providing clinically complex medical devices and solutions which Make Life's Experiences Possible
As of June 30, 2020, the company had TTM revenue of $883M and 3,600 associates worldwide
The company primarily targets western-based reimbursement geographies in Europe, North America and Asia Pacific
WHAT WE DO
Invacare is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings
The company's durable medical devices and solutions are designed for congenital, acquired, degenerative,
conditions that help people to move, breathe, rest and perform essential hygiene for 24-hours of care
Invacare sells its products to private and government medical equipment providers and residential care providers
Invacare Investor Presentation - September 9, 2020
I O N
Solutions Across The Continuum Of Care
Providing essential clinical solutions for broad range of conditions
Solution Areas (24-Hours of Care)
C O R P O R A T
Move
Custom power and manual wheelchairs and custom seating
- Alternative drive controls and touch-screen technology
- Informatics
Rest
Home care and long-term care beds and therapeutic support surfaces
- Pressure relief for wound healing and prevention
- Continued pressure monitoring
Breathe | Hygiene | |
Respiratory therapy products | Safe patient handling and hygiene | |
▪ | Stationary and portable | ▪ Patient transfer and bathing |
oxygen concentrators | equipment ensures resident and | |
▪ | HomeFill® Oxygen systems | caregiver safety |
▪ Daily hygiene products |
I N V A C A R E
Conditions | Congenital | Acquired | Degenerative |
Stroke | Multiple Sclerosis | ||
Cerebral Palsy | Spinal Cord Injury | ALS | |
Muscular Dystrophy | Traumatic Brain Injury | COPD | |
Spina Bifida | Post Acute Recovery | Bariatric | |
Pressure Ulcers | Age Related | ||
Settings | |||
High Acuity | Invacare provides solutions outside high acuity settings | Low Acuity | |
Invacare Investor Presentation - September 9, 2020
Reported Net Sales *
ON | $450 | $883 | ||
$414 | ||||
I | $400 | Million* | ||
T | $366 | |||
A | $350 | |||
O R | ||||
$300 | ||||
O R P | millions) | $250 | ||
$200 | ||||
C | (in | |||
E | $150 | |||
A R | $100 | $78 | ||
C | $50 | |||
A | $25 | |||
V | $0 | |||
N | ||||
Lifestyles | Mobility & Respiratory | Other | ||
I | ||||
Seating | ||||
* TTM sales as of June 30, 2020
Invacare Investor Presentation - September 9, 2020
Broad Product Line with High Clinical Value
Lifestyles
Globally focused on home healthcare and post-acute care, including aids for daily living, walking aids, lifts, wheelchairs, beds and surfaces
Mobility & Seating
Custom power and custom manual wheelchairs, seating and positioning, and power add-ons
Respiratory
Stationary concentrators and ambulatory oxygen such as portable concentrators and refilling devices for portable tanks
Other
Services and rentals
C O R P O R A T I O N
Strong Global Presence
$497M | $346M |
Europe (56%)* | North America (39%)* |
$40M
Asia Pacific (5%)*
I N V A C A R E
Primarily single payor reimbursement systems which appreciate durable medical equipment and total lowest cost of ownership
Key markets focused on Western Europe: France, Germany, UK, Benelux and the Nordic countries with a smaller presence in southern Europe
Manufacturing facilities in Germany, France, Portugal, UK and Sweden
* TTM sales as of June 30, 2020
Primarily sell to durable medical equipment providers, equipment fleet owners, residential care facilities and government agencies
Manufacturing facilities in the U.S., Mexico and Canada
Primarily target western-based reimbursement countries, such as Australia and New Zealand
Sales and distribution facilities in Australia, New Zealand and Thailand
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Transformation Plan Highlights
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Transformation Accomplishments Since 2015
Area | Accomplishment |
Quality / Regulatory | Developed a culture of quality in all regions |
Management | Appointed new CEO in 2015 to implement transformation |
Diversified and refreshed Board of Directors with 66% less than 5-year tenure | |
Hired CIO to drive modernization of IT systems and implementation of global ERP system | |
Enhanced North American sales organization and EMEA leadership team | |
Cost Optimization | Executed footprint rationalization and restructuring activities in all regions for cost savings of $39 million |
Executed supply chain actions to mitigate substantial portion of U.S. tariffs | |
Product Portfolio | Continue to introduce innovative new products which offer compelling clinical value |
Strategically exited low-margin products, which right-sized revenues to significantly reduced operating loss | |
Divested non-core business units and redeployed proceeds into growing the business | |
Financial Performance | TTM 2Q20 Free Cash Flow significantly improved compared to the Free Cash Flow usage since 2016 |
Successfully executed multiple transformative actions to reshape the
business since 2015 with more to come
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Initiatives Accelerating Our Transformation
Award winning clinical solutions and full product pipeline:
- Launched center-wheel and front-wheel drive standing positioning system with clinical and social benefits of vertical positioning, including pediatric standing system
- First wirelessly remote-controlled portable oxygen concentrator
- First with hydroforming technology that allows production of manual wheelchairs with significantly higher performance without increased weight
- Invacare Ampla Action bariatric wheelchair - winner of the Red Dot Award: Product Design 2019, Platinum A'Design Award, and German Design Award 2020
Operational improvements to expand margins and accelerate profitability:
- Benefit of expanded gross profit from plant consolidations in France
- Implementing plant consolidations in German facilities to be completed in late 2020
- Achieved significant improvement in material and freight costs through proactive supply chain actions
Partnership with Birlasoft Solutions to modernize business with flexible IT systems to:
- Drive operational efficiencies
- Improve our customers' experience
- Generate substantial cost savings
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Innovation Pipeline
Supporting sales growth with frequent introduction of clinically innovative solutions
Aug
Invacare® TDX® SP2 w/
LiNX® technology
Rovi® X3 with gyro and high-speed motors
Top End® EliminatorTM | May | ||||||||||||||||||||||||||||||||||||||||||
Feb | |||||||||||||||||||||||||||||||||||||||||||
Invacare® Top End® | NRG Racing Chair | SMOOV | |||||||||||||||||||||||||||||||||||||||||
Preliminator racing | One™ Power | ||||||||||||||||||||||||||||||||||||||||||
wheelchair | May | Add On | |||||||||||||||||||||||||||||||||||||||||
May | E-pilot P15 | ||||||||||||||||||||||||||||||||||||||||||
Power Add | |||||||||||||||||||||||||||||||||||||||||||
Cruise Mode | |||||||||||||||||||||||||||||||||||||||||||
on Alber® | On | ||||||||||||||||||||||||||||||||||||||||||
Mar | |||||||||||||||||||||||||||||||||||||||||||
Twion® power | |||||||||||||||||||||||||||||||||||||||||||
Invacare® | |||||||||||||||||||||||||||||||||||||||||||
Sep | |||||||||||||||||||||||||||||||||||||||||||
Orion | assist device | ||||||||||||||||||||||||||||||||||||||||||
Invacare® | |||||||||||||||||||||||||||||||||||||||||||
and Comet | |||||||||||||||||||||||||||||||||||||||||||
Action® manual | |||||||||||||||||||||||||||||||||||||||||||
Scooters | |||||||||||||||||||||||||||||||||||||||||||
wheelchairs | |||||||||||||||||||||||||||||||||||||||||||
2017 | 2019 | ||||||||||||||||||||||||||||||||||||||||||
2018 | |||||||||||||||||||||||||||||||||||||||||||
Apr | |||||||||||||||||||||||||||||||||||||||||||
Jan | |||||||||||||||||||||||||||||||||||||||||||
Invacare | |||||||||||||||||||||||||||||||||||||||||||
Bed | Stand Assist | ||||||||||||||||||||||||||||||||||||||||||
Oct | Sep | ||||||||||||||||||||||||||||||||||||||||||
safety | |||||||||||||||||||||||||||||||||||||||||||
Ocean Ergo | |||||||||||||||||||||||||||||||||||||||||||
and | Enhanced | ||||||||||||||||||||||||||||||||||||||||||
hygiene | Platinum® | Commode | May | ||||||||||||||||||||||||||||||||||||||||
May | |||||||||||||||||||||||||||||||||||||||||||
products | Mobile® | chair | |||||||||||||||||||||||||||||||||||||||||
May | Birdie Evo | ||||||||||||||||||||||||||||||||||||||||||
Birdie Evo | |||||||||||||||||||||||||||||||||||||||||||
Outcomes by | concentrator | Xplus Lifter | |||||||||||||||||||||||||||||||||||||||||
Lifter | |||||||||||||||||||||||||||||||||||||||||||
DesignTM | with | ||||||||||||||||||||||||||||||||||||||||||
post-acute | Connectivity | NordBed | |||||||||||||||||||||||||||||||||||||||||
solutions |
Rehab (Mobility and
Seating)
Post Acute Care (Lifestyle)
Respiratory
Mar | |||||||||
AVIVA FX / | |||||||||
AVIVA RX | |||||||||
Power | |||||||||
Sep | |||||||||
Wheelchairs | |||||||||
MPS Maxx | |||||||||
Modular Power | |||||||||
Standing System | Apr | ||||||||
MPS Mini | |||||||||
Maxx | |||||||||
Standing | |||||||||
System | |||||||||
2020
Sep
Platinum®
Mobile® concentrator with remote control functionality
Invacare Investor Presentation - September 9, 2020
Track Record of Optimization
Aligning footprint with new commercial strategy and sales level
C A R E C O R P O R A T I O N
Oct 31 | ||||||||||||||||
Headcount | ||||||||||||||||
reduction | ||||||||||||||||
Jan 31 | ||||||||||||||||
Kirkland, Ontario | ||||||||||||||||
manufacturing | ||||||||||||||||
facility closure; | ||||||||||||||||
Headcount | ||||||||||||||||
reduction | ||||||||||||||||
Dec 1 | ||||||||||||||||
Dallas, Texas | May 30 | |||||||||||||||
DC closure | Aug 1 | |||||||||||||||
Cranberry, NJ | Headcount | |||||||||||||||
DC Closure | reduction | |||||||||||||||
2016 | 2017 |
Jun 26
Suzhou, China manufacturing facility closure announced
Jan 31 | |||||||
Headcount | |||||||
reduction | |||||||
2Q18 | |||||||
Dio, Sweden | |||||||
Dec 7 | |||||||
Headcount | wheelchair | ||||||
reduction | production | ||||||
transfer | |||||||
completed | |||||||
2018
4Q18
Headcount reduction
1Q19
Küschall Switzerland wheelchair production transfer completed
2019
Apr 30
Atlanta DC
Closure
Dec
Announced
German
plant
consolidation
2Q19
Headcount reduction
2020
I N V A
Jul 2 | ||||
Sep 30 | ||||
Invacare Rentals | ||||
Garden City Medical | ||||
divestiture | ||||
divestiture | ||||
Annualized revenue | ||||
Annualized revenue $36.4M | ||||
$28.8M at 2015 run | ||||
at 2016 run rate | ||||
rate | ||||
$39 million in cost optimization actions executed from 2017 to date
Mar 7
Dynamic Controls divestiture Annualized revenue $17.2M
at 2019 run rate
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Transformation Highlights
We are transforming to regain market leadership
We have a clear roadmap to further enhance
Key | and simplify our operations |
Takeaways
We have a strong pipeline of innovative products coming to market
Our financial performance is improving as a result of these initiatives
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Financial Performance
Invacare Investor Presentation - September 9, 2020
Second Quarter 2020 Financial Highlights
I N V A C A R E C O R P O R A T I O N
Operating Loss
Improved $2.3 million due to:
- Reduced SG&A expenses
- Higher gross margin of 130 basis points partially offset by higher restructuring costs
- North America returned to profitability, generating $4.8 million of operating income
2Q19 2Q20
$0.0
($1.0)
($2.0)
($2.2)
($3.0)+50%
($4.0)
($5.0)($4.5)
Adjusted EBITDA
Improved $3.0 million driven by:
- $8.8 million reduction in constant currency SG&A expenses
- Partially offset by lower total sales and gross profit
- Favorable sales mix of higher acuity products
$8.0
$6.6
$6.0
+84%
$4.0$3.6
$2.0
$0.0
2Q19 2Q20
Free Cash Flow
Decreased by $2.1 million due to:
- Increased capital expenditures
- Higher inventory partially offset by higher A/P and payment deferrals
2Q19 2Q20
$1.0
$0.3
$0.0
($1.0)
($2.0)
($1.9)
Transformation initiatives and strong cost containment measures drive improved profitability
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
$160
$140
$120
$100
$80
$60
$40
$20
$0
Reported Net Sales
(in millions)
$5 | $5 | $4 | ||
$5 | $4 | |||
$5 | $5 | |||
$5 | $5 | |||
$5 | ||||
$64 | $5 | |||
$54 | $63 | $68 | $6 | |
$53 | ||||
$40 | ||||
$62 | $61 | $59 | $64 | $58 | $52 |
1Q19 | 2Q19 | 3Q19 | 4Q19 | 1Q20 | 2Q20 | |||||||
Lifestyles | Mobility & Seating | Respiratory | Other | |||||||||
PERFORMANCE BY SEGMENT - Europe
Segment Highlights
56% of total reported net sales on a TTM basis as of 6/30/20
Grow profitable sales from introduction of new products in all categories
Gross profit expansion from plant consolidations in France and Germany (to be completed in 2020)
Leverage supply chain capabilities and reduce the cost and complexity of the legal infrastructure
Realized benefits of cost reduction actions executed mid-2019
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
$100
$90
$80
$70
$60
$50
$40
$30
$20
$10
$0
Reported Net Sales
(in millions)
$0 | $0 | $0 | $0 | $0 | $0 |
$14 | |||||
$14 | $12 | $11 | $15 | ||
$20 | |||||
$28 | $30 | $31 | $32 | $30 | $26 |
$43 | $45 | $43 | $42 | $43 | $41 |
1Q19 2Q19 3Q19 4Q19 1Q20 2Q20
Lifestyles | Mobility & Seating | Respiratory | Other | |||
PERFORMANCE BY
SEGMENT - North
America
Segment Highlights
39% of total reported net sales on a TTM basis as of 6/30/20
Continue to grow market share in Mobility & Seating driven by new product introductions and improved commercial effectiveness
Respiratory sales and margins improving with favorable mix and higher demand due to COVID-19
Gross profit expansion including leveraging supply chain capabilities and portfolio rationalization
SG&A leverage including benefit of cost reductions
Continue to invest in systems to accelerate growth in e-commerce and cost savings from improved operating efficiencies
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Reported Net Sales
(in millions)
$14
$12
$2 | $2 | |||||||||||||
$0 | $1 | $1 | $2 | |||||||||||
$10 | $0 | $1 | ||||||||||||
$0 | ||||||||||||||
$1 | ||||||||||||||
$8 | ||||||||||||||
$1 | ||||||||||||||
$8 | ||||||||||||||
$7 | $7 | $0 | ||||||||||||
$6 | ||||||||||||||
$6 | $5 | |||||||||||||
$3 | ||||||||||||||
$4 | ||||||||||||||
$2 | ||||||||||||||
$3 | $3 | $4 | ||||||||||||
$3 | $3 | $3 | ||||||||||||
$0 | ||||||||||||||
1Q19 | 2Q19 | 3Q19 | 4Q19 | 1Q20* | 2Q20* | |||||||||
Lifestyles | Mobility & Seating | Respiratory | Other | |||||||||||
- Excludes sales from Dynamic Controls as of March 7, 2020 Invacare Investor Presentation - September 9, 2020
PERFORMANCE BY
SEGMENT - All Other
(Asia Pacific)
Segment Highlights
5% of total reported net sales on a TTM basis as of 6/30/20
Historically, this segment included the Australia and New Zealand distribution businesses and Dynamic Controls, a designer and manufacturer of control systems for power mobility products.
Effective 1Q20, the Company sold its Dynamic Controls business which represented revenues of $17.2M for the full year 2019 (included in Mobility & Seating)
I N V A C A R E C O R P O R A T I O N
Balance Sheet Supports Transformation
As of June 30, 2020
Debt * | Cash |
Total Debt of $319 million | Total Cash increased to $104 million due |
- $37 million drawn on the ABL credit | to: |
facility and government loan programs | - Cash borrowed on the company's |
- $254 million in convertible debt | credit facility |
- $28 million of other debt, primarily | - Proceeds from the sale of Dynamic |
financing leases | Controls |
- On Jun 5, 2020, the company extended | - Government loan programs |
the debt maturities of a significant | - Partially offset by cash used to fund |
portion of its 2021 and 2022 Notes, | operations and cash paid to extend a |
until Nov 2024 | portion of convertible debt in 2Q20 |
Balance Sheet Highlights
The company has accessed global government programs to bolster short-term liquidity including the temporary delay of direct and indirect tax payments
The company has a U.S. Federal tax loss carryforward and tax credits in excess of $377 million as of December 31, 2019
The company continues to believe that generation of Adjusted EBITDA driven by operational
performance, cash balances on hand, and expected free cash flow will support the company's
ongoing transformation plans and enable it to address future debt maturities
* Excludes $15.9 million in operating lease obligations capitalized on the balance sheet
Recent Events
As of Sep 4, 2020, the company repurchased approximately $22 million of the 2021 Convertible Notes at a slight discount to par
Convertible Debt Maturities | |||
$160 | (as of 9/4/20) | $146.8 | |
$140 | |||
$120 | |||
$100 | $81.5 | ||
$80 | |||
$60 | |||
$40 | |||
$20 | $3.8 | ||
$0 | |||
Feb 2021 | Jun 2022 | Nov 2024 | |
Invacare Investor Presentation - September 9, 2020
COVID-19 Business Dynamics
Driving Two Patterns of Demand; Phasing of Peak and Return with Recovery
I N V A C A R E C O R P O R A T I O N
Anatomy of Impact
Early ramp in Respiratory and Bed demand to support COVID-19 care
demand | |
normal% | 2Q20 |
Elevated Respiratory demand continues
Past COVID-19 bed peak offset by limited long- term care access
time
Mobility & Seating past bottom as clinic / healthcare access returns
Respiratory and Beds/Lifestyles
- Strong demand for stationary oxygen concentrators for COVID-19 response; began in late 1Q20 and continues today
- Smaller peak for bed systems - initial strong demand for expanded medical facilities and post-discharge home care offset by lower demand from limited access to residential care facilities and lower demand for post-elective surgery care. 2Q20 COVID-19 peak has passed; residential care facility access and elective procedures expected to resume
- Timing of return to more normal sales rates TBD based on course of pandemic
Mobility & Seating
- Good momentum in 1Q20 driven by power mobility products with new product growth and improved commercial effectiveness
- Limited access to clinicians from late-1Q20 for custom fitting reduced sales
- Order volume expected to increase as access to clinicians enables custom fittings and deliveries
All Products
NB - For illustrative purposes only; not drawn to scale
- Overall, higher value sales mix due to lower demand of low acuity products and elective procedures, which were delayed due to public health measures
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
COVID-19: Financial and Operating Assumptions
Revenue
- Sequential increase in consolidated net sales in 2020, staying lower than prior year
- Europe expected to recover more slowly than the U.S. due to more stringent public healthcare restrictions
- Mobility & seating impacted by limited access to healthcare facilities, expected to begin recovery with the resumption of elective care
- Elevated demand for respiratory products related to the pandemic
Expenses & Margins
- Gross margins expected to be impacted as product mix returns to more normalized levels
- Operational and cost management actions implemented to mitigate margin dilution:
- Limiting the number of product models being sold to improve manufacturing efficiency
- Implemented salary reductions for senior executives and the Board of Directors
- Added temporary surcharges on certain orders to mitigate increase from expediting materials
- Reducing discretionary spending
Balance Sheet & Cash
- Preemptively borrowed under the bank credit facility
- Accessed government-based loans and other programs which bolster short-term liquidity, including loans and temporary delays of direct and indirect tax payments
- Extended a significant portion of convertible debt maturing in 2021 and 2022, to 2024
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Our Products
Invacare Investor Presentation - September 9, 2020
Mobility & Seating - Custom Power and Manual
I N V A C A R E C O R P O R A T I O N
MPS Maxx Modular Power
Standing System and Mini Maxx
- Innovative center-wheel drive powerchair with clinical and social benefits of vertical positioning
- Fits fully within Group 3 reimbursement in the U.S.
AVIVA FX (U.S.) and
AVIVA RX (Europe)
- Advanced seating and positioning systems
- Unique suspension systems resulting in a smooth stable ride
- Standing capabilities on FWD platform
Kuschall
Custom Manual
- Unique hydroforming technology resulting in a stiffer frame without added weight
Invacare Investor Presentation - September 9, 2020
C O R P O R A T I O N
Mobility & Seating - Electromotive Technology
Applying power add-on technology to new products, including recreational mobility devices and extension apps
E-Bike Drive Systems | ||||
Power Handbike | Power Assist | Power Assist | ||
I N V A C A R E
- Dynamic market growth
- Alber launched new product generation in July 2018 (neodrives Z20)
- Superior driving performance (silent, dynamic, highly efficient state-of-the art hub motor technology)
- Note: Invacare sells the motor, not the complete e-bike
- Launched in Europe May 2018
- First power handbike with fully integrated Lithium-Ion battery
- Easy and fast coupling workflow
- Integration of neodrives drive system
- 20 km/h (12.4 mph) top speed
- Connectivity app
- Electric motors equipped with leading-edge digital electronics provide consumer with extra power for every propelling movement
- Assists with speed up to 8,5 km/h (5.3 mph)
- Lightweight and quiet
- Option of Smartphone connectivity with Bluetooth interface (510(k) pending)
- Launched in Europe May 2019; FDA 510k clearance Jun 2020
- Easy mounting to manual wheelchairs
- Small, lightweight, easy to travel with
- 10 km/h (6.2 mph) top speed, range of 20 km (12.4 miles) and supports body weight up to 140 kg (309 lbs.)
- Ergonomic user interface
- Connectivity app
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Mobility & Seating - Sports and Recreation
Daniel Romanchuk, in a Top End®
Eliminator TM NRG Racing
Wheelchair
Winner (Push rim division):
2018, 2019 New York Marathon
2018, 2019 Chicago Marathon
2019 World Para Athletics world
record (5000 meters)
2019 London Marathon
2019 Boston Marathon
Learn more about Top End at: https://topendwheelchair.invacare.com/
Invacare Investor Presentation - September 9, 2020
Lifestyles - Beds and Safe Patient Handling
For home healthcare and long-term care settings
I N V A C A R E C O R P O R A T I O N
Invacare Investor Presentation - September 9, 2020
Respiratory - Ambulatory Solutions
I N V A C A R E C O R P O R A T I O N
HomeFill® Refilling Systems
Benefits for Patients
- Unlimited refillable oxygen supply
- Easy to use and reliable
- Quiet, no heat, no vibrating*
Benefits for Providers
- Longer durability; requires little to no maintenance, fewer unplanned calls
- No battery or sieve bed replacements**
- Continuous flow & pulse dose capable
- Lower total cost of ownership
Industry's #1 durable, reliable, low total cost of ownership, preferred ambulatory product***
- HomeFill cylinder while in use
- Other than stationary concentrator requirements
- Ambulatory Devices include refilling devices, portable, transportable & stationary oxygen concentrators, oxygen cylinders & liquid oxygen. Results based on Invacare's customer feedback - 125 respondents nationwide
Premium Platinum Mobile Features
- First truly hands free POC with app-enabled remote flow control
- Enables flow control from up to 25ft from device, shows battery time remaining in hrs. and mins, comprehensive information hub for patient
- Provider portal helps drive lower total cost of ownership
- Integrated system drives value for both provider and patient
- Easiest battery management system
- Top-loadfeature: never remove bag to insert batteries
- Hot-swapcapable: never interrupt O2 supply to swap batteries
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Appendix
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Highly Engaged and Diversified Board of Directors
Governance, insight and strong industry experience to guide Invacare and represent shareholders' interests
C. Martin Harris, | Petra | |||||||
M.D. | Susan H. | Julie | Danielsohn-Weil, | Diana S. | Marc M. | Matthew E. | Clifford D. | Baiju R. |
(Lead Director) | Alexander | Beck | Ph.D. | Ferguson | Gibeley | Monaghan | Nastas | Shah |
Associate VP, | Executive VP, | CFO, NOVA | Retired, former | Principal and | CEO, Nutritional | Chairman, | CEO & President, | Managing | ||||||
Health Enterprise | Chief Legal | Chemicals | Regional | Founder, Scarlett | Medicinals, LLC | President and | Tempel Steel | Director, | ||||||
& Chief Business | Officer and | Corporation | President, Pfizer | Investments LLC | CEO, Invacare | Accelevate | ||||||||
Officer, Dell | Secretary, Biogen | Essential Health - | Ventures | |||||||||||
Medical School at | Europe | |||||||||||||
U. of Texas | ||||||||||||||
CEO | ||||||||||||||
Healthcare | ||||||||||||||
International | ||||||||||||||
Financial | ||||||||||||||
Turnaround | ||||||||||||||
0-5 years | ||||||||||||||
Diversity* | ||||||||||||||
Independent | ||||||||||||||
Public | ||||||||||||||
NYSE: TMO, NYSE: CL, | NASDAQ: BIO | NYSE: NOVA | NYSE: PFE | NYSE: SBH, | SIX: RO | NASDAQ: SYNH, | NASDAQ: MASC | NYSE: CFG | ||||||
Company | NASDAQ: HSTM | Chemicals | NASDAQ: MAT, FTR | NYSE: ZBH | ||||||||||
* Based on race, gender, ethnicity
Invacare Investor Presentation - September 9, 2020
Experienced Management Team
Motivated team with years of international and healthcare industry experience
I N V A C A R E C O R P O R A T I O N
Executive Management
Matt Monaghan
Chairman, President and Chief Executive Officer
Tenure: 5 years
Experience: Healthcare, business turnaround, engineering, finance, private equity
Kathy Leneghan
SVP & Chief Financial Officer
Tenure: 29 years
Experience: International finance, public audit
John Watkins
SVP, Quality Assurance & Regulatory Affairs Tenure: 4 years
Experience: Quality, regulatory and operations in healthcare, manufacturing, engineering, planning, sourcing, Six Sigma
Executive Management
Anthony LaPlaca
SVP, General Counsel, Chief Administrative Officer & Secretary
Tenure: 11 years
Experience: Legal, risk management, corporate governance, intellectual property, human resources, corporate communications, national law firm
Angela Goodwin
Chief Information Officer
Tenure: 1 year
Experience: Global IT and ERP implementation
Business Leaders
Ralf Ledda
SVP & GM, Europe Tenure: 23 years
Experience: Industrial engineering, electromotive technology, lean production system, medical device commercialization
Geoff Purtill
VP & GM, Asia Pacific
Tenure: 9 years
Experience: Sales, marketing, customer service, supply chain, medical device commercialization
Joost Beltman
SVP & GM, North America
Tenure: 12 years
Experience: Sales, marketing, commercial leadership, customer service, post-merger integration, supply chain
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Convertible Debt Summary
Terms | 2021 | 2022 | 2024 Series I | 2024 Series II | Total |
Amount (as of Sep 4, 2020) | $3.8M | $81.5M | $72.9M | $73.9M | $232.0M |
Maturity date | Feb 15, 2021 | Jun 1, 2022 | Nov 15, 2024 | Nov 15, 2024 | -- |
Interest rate | 5.0% | 4.5% | 5.0% | 5.0% | 4.8% |
Conversion price | $16.65 | $16.23 | $14.78 | $14.78 | -- |
Soft call price | -- | -- | $19.21 | $19.21 | -- |
Contingent conversion price * | $21.65 | $21.10 | -- | -- | -- |
Warrant price | $22.42 | $21.44 | -- | -- | -- |
Maximum debt accretion** | -- | -- | -- | $16.6M | |
Convertible debt quote at 9/8/20 | 98.7 | 86.1 | 83.2 | 87.1 | -- |
Potential share dilution (in millions)***: | |||||
IVC stock at $10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
IVC stock at $15 | 0.00 | 0.00 | 0.07 | 0.07 | 0.14 |
IVC stock at $20 | 0.00 | 0.00 | 1.29 | 1.31 | 2.60 |
*Price at which share dilution can occur
- The additional accretion is only payable in cash by Invacare if bond holders do not convert at or prior to the maturity date
- Based on 34.4 million shares outstanding as of 6/30/20 and assuming net share settlement
Invacare Investor Presentation - September 9, 2020
I N V A C A R E C O R P O R A T I O N
Reconciliation of Non-GAAP Performance Metrics to GAAP Financial Measures
Non-GAAP Financial Measures
Some of the information in this presentation is derived from the company's consolidated financial data but not presented in its financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP). Certain of these data are considered "non-GAAP financial measures" under Securities and Exchange Commission rules. These non-GAAP financial measures supplement the company's GAAP disclosures and should not be considered an alternative to the GAAP measure. The reconciliations to their most directly comparable GAAP financial measures are included in Appendix A of the 1Q20 earnings release. The company uses non-GAAP financial measures including the following:
"Adjusted EBITDA" is EBITDA plus equity compensation and charges related to restructuring activities.
"Adjusted net loss" is net earnings (loss) before income taxes net of adjusted income taxes.
"Constant currency net sales" is net sales excluding the impacts of foreign currency translation and divestiture.
"Constant currency SG&A" is SG&A excluding the impacts of foreign currency translation and divestiture.
"EBITDA" is net earnings (loss) from continuing operations plus: income taxes, interest expense-net, net gain or loss on debt extinguishment including debt financing charges and fees, net gain or loss on convertible debt derivatives, gain/loss on sale of business, asset write-downs related to intangible assets, and depreciation and amortization.
"Free cash flow" is net cash provided (used) by operating activities less purchases of property and equipment plus proceeds, including the advances from sales of property and equipment.
(Dollars in millions) | 2Q19 | 2Q20 | ||
Net Loss | (12.7) | (16.6) | ||
Income Taxes | 2.1 | 0.7 | ||
Income Loss Before Taxes | (10.6) | (15.9) | ||
Interest Expense* | 7.7 | 13.7 | ||
Interest Income | (0.1) | (0.0) | ||
Net Gain on Convertible Debt Derivatives | (1.5) | - | ||
Operating Loss | (4.5) | (2.2) | ||
Operating Loss | (4.5) | (2.2) | ||
Depreciation and Amortization | 3.9 | 3.3 | ||
Gain on Sale of Business | - | (0.2) | ||
EBITDA | (0.6) | 0.8 | ||
Restructuring Charges | 1.3 | 1.7 | ||
Stock Compensation | 2.9 | 4.1 | ||
Adjusted EBITDA | 3.6 | 6.6 | ||
Net Cash Provided (Used) by Operating Activities | 2.7 | 6.5 | ||
Plus: Sales of Property and Equipment, including advances | (0.0) | (0.4) | ||
Less: Purchases of Property and Equipment | (2.5) | (8.8) | ||
Free Cash Flow | 0.3 | (1.9) | ||
Reported Net Sales % Change | -4.2% | -16.8% | ||
Less: Foreign Exchange Impact | -4.8% | -1.9% | ||
Less: Impact of Divested Entities | 0.0% | -2.0% | ||
Constant Currency Sales % Change | 0.6% | -12.9% | ||
Reported SG&A % Change | -7.5% | -15.9% | ||
Less: Foreign Exchange Impact | -3.7% | -1.0% | ||
Less: Impact of Divested Entities | 0.0% | -1.7% | ||
Constant Currency SG&A % Change | -3.8% | -13.2% | ||
* includes loss on debt extinguishment including fin charges & fees
Invacare Investor Presentation - September 9, 2020
Attachments
- Original document
- Permalink
Disclaimer
Invacare Corporation published this content on 09 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2020 08:23:59 UTC